# Bristol-Myers Squibb Company (BMY) — Q4-2022 Earnings Results

**Report date:** 2023-02-02 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q4-2022

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 2.16%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.82 | N/A | +6.25% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their product performance. They emphasized the importance of their pipeline while recognizing external market pressures.

**Key quotes:**

> Management highlighted the continued strength of their key products.

> They expressed confidence in their pipeline but acknowledged market challenges.

> The focus remains on innovation and maintaining competitive positioning.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which contributed to a 2.16% increase in stock price. The management's cautious optimism reflects confidence in their product pipeline despite ongoing market challenges. Investors may view this as a sign of resilience in the company's operations.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q4-2022_